AbbVie press release (NYSE:ABBV): Q2 Non-GAAP EPS of $2.97 beats by $0.06.
Revenue of $15.42B (+6.6% Y/Y) beats by $390M.
Second-Quarter Global Net Revenues from the Immunology Portfolio Were $7.631 Billion, an Increase of 9.5 Percent on a Reported Basis, or 9.2 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.423 Billion; Global Rinvoq Net Revenues Were $2.028 Billion; Global Humira Net Revenues Were $1.180 Billion
Raises 2025 Adjusted Diluted EPS Guidance Range from $11.67 – $11.87 to $11.88 – $12.08 vs. $11.98 consensus, which Includes an Unfavorable Impact of $0.55 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the Second Quarter 2025
